Business Wire

Modernizing the Global Postal System: Zonos Selected by the Universal Postal Union (UPU) to Power Enhanced Compliance, Processing Speed, and Transparency for Posts Worldwide

4.9.2024 17:00:00 EEST | Business Wire | Press release

Share

In a groundbreaking move to address the dual challenges of evolving compliance regulations and increasing consumer expectations for swift, efficient deliveries, Zonos, the leader in cross-border technology solutions, has been selected by the Universal Postal Union (UPU) for a strategic initiative. The UPU is a United Nations specialized agency that facilitates international postal cooperation through its universal network of modern postal services. By leveraging Zonos' cutting-edge API technology to enhance the accuracy and processing speed of data transmitted through the UPU's Customs Declaration System (CDS), this effort is poised to transform the global postal ecosystem. This initiative aims to empower postal operators with technology to mitigate delays caused by inadequate or incomplete data, thereby improving operational efficiency, ensuring compliance, and significantly enhancing the delivery experience for consumers worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904490189/en/

The international DDP shipping model allows parcels to ship with duties, taxes, and fees prepaid, making it easy for packages to move through customs. (Graphic: Business Wire)

Bridging the Technological Divide for Postal Operators Worldwide

This partnership specifically targets the technological challenges faced by postal operators around the globe. Many of these entities struggle to compete in an increasingly digital and data-driven landscape due to their limited ability to accurately and rapidly transmit electronic advanced data (EAD). This deficiency places them at a competitive disadvantage and contributes to significant delays in the international customs clearance process.

Zonos' innovative API technology offers a scalable and adaptable technology solution to these challenges, facilitating real-time, accurate data collection that meets the rigorous requirements of modern customs and security regulations that require detailed shipment information including good descriptions, harmonized codes, and accurate values for general or regional (such as ICS2) EAD regulations. The improved data quality addresses regulatory and safety concerns about the contents of packages for global customs operations.

Transitioning to a Delivered Duty Paid (DDP) Model

A significant goal of this collaboration is to transition towards a DDP model in response to market demand for more transparent and efficient customs processes. This initiative supports the UPU's Article 18-004 (Items for delivery free of charges and fees) by developing a robust DDP solution, facilitating smoother and faster cross-border mail and parcel deliveries. By enabling posts to calculate and collect duties and taxes at the point of sale, this model eliminates surprise costs for consumers and enhances the overall international mailing and delivery experience.

Enhancing Consumer Experience through Efficiency and Reliability

The UPU-Zonos initiative emphasizes improving the delivery experience for consumers worldwide. By streamlining the data collection process, the partnership aims to expedite customs clearance and reduce the time packages spend in transit to meet the consumer demand for speed. It also aims to enhance the reliability and predictability of international deliveries, fostering greater trust in the global postal system.

A Unified Vision for the Future of International Postal Services

The shared commitment of the UPU and Zonos to leveraging technology for the betterment of the global postal ecosystem is at the heart of this initiative. Clint Reid, CEO of Zonos, echoed this sentiment, highlighting the transformative potential of the collaboration: "Together, we are not just addressing immediate challenges; we are paving the way for a future where international postal services are more secure, efficient, and transparent for all."

About Zonos

Zonos is a leader in technology innovation for international commerce, simplifying cross-border trade with its comprehensive suite of solutions. Focused on compliance, classification, and transparent cost calculation, Zonos empowers businesses and postal operators to expand their global reach effortlessly, making international trade more accessible and transparent.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904490189/en/

Contacts

Jennifer Meads, Head of Marketing at Zonos
media@zonos.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior

European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

CORRECTING and REPLACING Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival29.4.2026 11:49:00 EEST | Press release

Headline of release dated April 27, 2026 should read: Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival The updated release reads: YOSHIHIRO SHIMAMURA, A LEADING INVESTOR IN JAPAN’S ENTERTAINMENT INDUSTRY, TO HOST WORKSHOP AT THE 2026 CANNES FILM FESTIVAL Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of

Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 11:27:00 EEST | Press release

OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,

The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 11:00:00 EEST | Press release

Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, where human creativity is renewed through technology. Leading the jury will be Gabriele Salvatores, Italian director and screenwriter known for films such as Nirvana, Siberian Education, and Napoli - New York, and Academy Award® winner for Best Foreign Language Film with Mediterraneo. Joining him on the panel for the third edit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye